Botox is a revolutionary anti-aging treatment that temporarily paralyzes targeted muscle areas to improve the look of wrinkles and frown lines on your face. Since its launch in 1989 and FDA-approval in 2002, Botox has become a common household name. Our patients have found Botox to be an extremely effective way to improve their appearance and to help restore their youthful look.

What about Dysport/Xeomin? Which Neurotoxin is better?

Most of our patients are familiar with Botox treatment, which has been a popular anti-aging treatment for over 15 years. Today, there are several alternatives: Dysport was approved in 2009, while Xeomin was approved in 2010.

All three injectables are made from the same source bacterium and synthesized as botulinum toxin type A, which works by blocking nerve impulses of targeted muscles to temporarily stop muscle movement responsible for wrinkles. However, they undergo different manufacturing processes that result in subtle differences in their clinical applications.

For instance, Dysport offers a more even distribution for treating facial muscles between eyebrows. Xeomin does not contain any additives, which makes it ideal for people with allergies or when other fillers become less effective (i.e. because the body developed antibodies against them). Botox is the most versatile and can be used to fix moderate to severe cases of frown lines and wrinkles.

Before After Dr Fakheri

With Dysport, you will typically see results after 24 hours. Botox can take 72 hours, while Xeomin may take up to 96 hours before noticeable changes are seen. These results typically last between 3 and 6 months. Thus, patients may have several periodic treatments to achieve their desired results.

Dr. Fakheri may use any of the three injectables to deliver the best results for each individual case. During your appointment, we can discuss your unique needs and create your custom treatment plan. To schedule your free cosmetic consultation today, please call 818-343-0101 or visit our office located in Tarzana, CA.